Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients

British Journal of Cancer

Volumn 97, Issue 10, 2007, Pages 1329-1332

  Atzpodien, J ^a,b   Terfloth, K ^a   Fluck, M ^a   Reitz, M ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Europaisches Institut fur Tumor Immunologie und Pravention EUTIP   (Germany)

Author keywords

Cisplatin; Gemcitabine; Melanoma; Treosulfan

Indexed keywords

BLEOMYCIN; CARMUSTINE; CISPLATIN; DACARBAZINE; FOTEMUSTINE; GEMCITABINE; HYDROXYUREA; RECOMBINANT ALPHA2A INTERFERON; TEMOZOLOMIDE; TREOSULFAN; TROFOSFAMIDE; VINBLASTINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; DRUG EFFICACY; DRUG FATALITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVERALL SURVIVAL; POLYNEUROPATHY; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, UNKNOWN PRIMARY; RECURRENCE; REMISSION INDUCTION; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 36148963293     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604045     Document Type: Article

References (13)

1. Atzpodien J, Neuber K, Kamanabrou D, Fluck M, Brocker EB, Neumann C, Runger TM, Schuler G, von den Driesch P, Muller I, Paul E, Patzelt T, Reitz M (2002) Combination chemotherapy with or without s.c. IL2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer 86(2): 179-184
2. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernsthoff MS, Houghton AN, Kirkwood JM (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17(9): 2745-2751
3. Cree IA, Neale MH, Myatt NE, de Takats PG, Hall P, Grant J, Kurbacher CM, Reinhold U, Neuber K, Mackie RM, Chana J, Weaver PC, Khoury GG, Sartori C, Andreotti PE (1999) Heterogeneity of chemosensitivity of metastatic cutaneous melanoma. Anticancer Drugs 10(5): 437-444
4. Hillner BE, Kirkwood JM, Atkins MB, Johnson ER, Smith TJ (1997) Economic analysis of adjuvant interferon-alfa-2b in high-risk melanoma based on projections from ECOG 1684. J Clin Oncol 15: 2351-2358
5. Huncharek M, Cubet JF, McGarry R (2001) Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 11(19): 75-81
6. Pfohler C, Cree IA, Ugurel S, Kuwert C, Haass N, Neuber K, Hengge U, Corrie PG, Zutt M, Tilgen W, Reinhold U (2003) Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a Multicenter Feasibility Study. Anticancer Drugs 14(5): 337-340
7. Richards JM, Mehta N, Ramming K, Skosey P (1992) Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10(8): 1338-1343
8. Schmittel A, Scheulen ME, Bechrakis NE, Strumberg D, Baumgart J, Bornfeld N, Foerster MH, Thiel E, Keilholz U (2005) Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. Melanoma Res 15(3): 205-207
9. Schmittel A, Schmidt-Hieber M, Martus P, Bechrakis N, Schuster R, Siehl J, Foerster M, Thiel E, Keilholz U (2006) A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol 17(12): 1826-1829
10. Serrone L, Zeuli M, Sega FM, Cognetti F (2000) Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 19(1): 21-34
11. Stein ME, Bernstein Z, Tsalic M, Drumea K, Steiner M, Sklar Z, Haim N (2002) Chemoimmunohormonal therapy with carmustine, dacarbazine, cisplatin, tamoxifen, and interferon for metastatic melanoma: a prospective phase II study. Am J Clin Oncol 25(5): 460-463
12. Ugurel S, Schadendorf D, Pföhler C, Neuber K, Thoelke A, Uhlrich J, Hauschild A, Spieth K, Kaatz M, Rittgen W, Delorme S, Tilgen W, Reinhold U (2006) In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res 12(18): 5454-5463
13. Ugurel S, Tilgen W, Reinhold U (2003) Chemosensitivity testing malignant melanoma. Recent Results Cancer Res 161: 81-92